PET imaging of amyloid deposition in patients with mild cognitive impairment.

By A. Forsberg, H. Engler, O. Almkvist, G. Blomquist, G. Hagman, A. Wall, Anna Ringheim, B. Långström, A. Nordberg. Neurobiology of Aging, 2008

721 citations recorded by the source corpus.

Subfields: Physiology, Psychiatry and Mental health, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/a9d02ecea97e046b5af89088f6654e9a589b2caa

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Physiology

In Psychiatry and Mental health

In Radiology, Nuclear Medicine and Imaging

Citations in the corpus

Serial PIB and MRI in normal, mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease (2009, positive): “Overall, these ﬁndings are in agreement with previously published cross-sectional PIB studies (Nordberg, 2004; Mintun et al ., 2006; Kemppainen et al ., 2007; Aizenstein et al ., 2008; Forsberg et al ., 2008; Li et al ., 2008; Mormino et al ., 2008; Sojkova et al ., 2008; Villemagne et al ., 2008).”
Brain imaging in Alzheimer disease. (2012, background): “In the setting of MCI, combined data from nine amyloid PET studies show that 161 of 272 MCI patients were amyloid positive (59%) (Fig. 4; Forsberg et al. 2008; Koivunen et al. 2008; Lowe et al. 2009; Okello et al. 2009; Tolboom et al. 2009; Wolk et al. 2009; Devanand et al. 2010; Jagust et al. 2010;”
Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease (2008, background): “PiB-PET is able to track Ab deposition across the spectrum of normal aging to advanced Alzheimer’s disease (Forsberg et al., 2007; Kemppainen et al., 2007; Rowe et al., 2007), and further histological studies will need to be performed to assess the relative contributions of different plaque types…”
11C PiB and structural MRI provide complementary information in imaging of Alzheimer's disease and amnestic mild cognitive impairment. (2008, background): “Greatest retention values are seen in prefrontal and lateral temporoparietal cortex, posterior cingulate/precuneus, and striatum (Edison et al., 2007; Engler et al., 2006; Forsberg et al., 2007; Kemppainen et al., 2006; Klunk et al., 2004; Mintun et al., 2006).”
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010, neutral): “Increased cortical uptake of 11 C-PIB is seen in 2 out of 3 of patients with mild cognitive impairment with probable progression to Alzheimer's diseas”
Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. (2009, background): “Classification of MCI subjects as PIB+ is motivated by research showing that MCI subjects with high PIB uptake are likely to convert to Alzheimer's disease (Forsberg et al., 2008).”
Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease (2009, background): “They are now being used in longitudinal studies to determine the extent to which asymptomatic fibrillar A burden, alone or in combination with other risk factors and measurements, predicts subsequent rates of cognitive decline and clinical conversion to mild cognitive impairment and AD (12).”